Jpmorgan Chase & CO Maia Biotechnology, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MAIA
# of Institutions
21Shares Held
673KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA282KShares$1.09 Million0.0% of portfolio
-
Centric Wealth Management67.2KShares$259,3840.05% of portfolio
-
Geode Capital Management, LLC Boston, MA53.3KShares$205,5720.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX45.7KShares$176,4020.0% of portfolio
-
Virtu Financial LLC New York, NY32.5KShares$125,3990.01% of portfolio
About MAIA Biotechnology, Inc.
- Ticker MAIA
- Exchange
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,935,900
- Market Cap $42.2M
- Description
- MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company wa...